Revolution Medicines (NASDAQ:RVMD) Given New $167.00 Price Target at Wells Fargo & Company

Key Points

• Wells Fargo raised its price target on Revolution Medicines (RVMD) to $167 from $144 and maintained an "overweight" rating, implying roughly a 16.6% upside from the current price.
• The company reported late‑stage Phase 3 success for experimental KRAS drug daraxonrasib—nearly doubling survival versus chemotherapy—which spurred broad media coverage and a sharp intraday stock rally to near its 52‑week high.
• Revolution also filed to raise capital—$750M of common stock and $250M of convertible senior notes—which could dilute shareholders, and insiders have sold shares recently (about 64,592 shares worth ~$6.49M in the past 90 days).

Revolution Medicines (NASDAQ:RVMD - Get Free Report) had its price target hoisted by Wells Fargo & Company from $144.00 to $167.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Wells Fargo & Company's price objective would suggest a potential upside of 16.62% from the company's current price.

A number of other equities research analysts also recently issued reports on the stock. Evercore reissued an "outperform" rating on shares of Revolution Medicines in a research report on Tuesday. UBS Group initiated coverage on shares of Revolution Medicines in a research report on Friday, February 27th. They set a "buy" rating for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Jefferies Financial Group initiated coverage on shares of Revolution Medicines in a research report on Monday, March 16th. They set a "buy" rating for the company. Finally, Truist Financial raised shares of Revolution Medicines to a "strong-buy" rating in a research report on Wednesday, March 25th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $84.65.

Revolution Medicines Stock Performance

NASDAQ:RVMD traded up $6.90 during trading hours on Tuesday, reaching $143.20. The company had a trading volume of 2,581,084 shares, compared to its average volume of 3,271,880. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16. Revolution Medicines has a 52 week low of $34.00 and a 52 week high of $143.75. The firm has a market cap of $28.38 billion, a price-to-earnings ratio of -24.16 and a beta of 1.01. The firm's 50 day moving average price is $98.90 and its 200-day moving average price is $83.55.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.30). During the same period last year, the company earned ($1.12) EPS. On average, analysts forecast that Revolution Medicines will post -3.49 EPS for the current year.

Insider Activity at Revolution Medicines

In other Revolution Medicines news, insider Lin Wei sold 2,073 shares of the business's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $206,222.04. Following the sale, the insider owned 101,366 shares in the company, valued at $10,083,889.68. The trade was a 2.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Margaret A. Horn sold 4,583 shares of the business's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $455,916.84. Following the completion of the sale, the chief operating officer owned 157,570 shares in the company, valued at approximately $15,675,063.60. The trade was a 2.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 64,592 shares of company stock worth $6,488,732 in the last 90 days. Company insiders own 8.20% of the company's stock.

Institutional Trading of Revolution Medicines

Several hedge funds have recently bought and sold shares of RVMD. Nextech Invest Ltd. lifted its stake in Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock worth $332,472,000 after purchasing an additional 1,304,347 shares in the last quarter. Millennium Management LLC lifted its stake in Revolution Medicines by 681.8% in the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company's stock worth $5,529,000 after purchasing an additional 136,353 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Revolution Medicines by 14.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company's stock worth $10,615,000 after purchasing an additional 37,345 shares in the last quarter. Invesco Ltd. lifted its stake in Revolution Medicines by 19.3% in the 2nd quarter. Invesco Ltd. now owns 227,019 shares of the company's stock worth $8,352,000 after purchasing an additional 36,760 shares in the last quarter. Finally, Jump Financial LLC increased its holdings in shares of Revolution Medicines by 87.9% in the 2nd quarter. Jump Financial LLC now owns 15,258 shares of the company's stock worth $561,000 after buying an additional 7,137 shares during the last quarter. Hedge funds and other institutional investors own 94.34% of the company's stock.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Late‑stage Phase 3 success — daraxonrasib nearly doubled typical survival and materially reduced risk of death versus chemotherapy, a result that materially derisks the program and supports future regulatory filings and commercialization potential. Revolution Medicines' experimental cancer pill helps improve survival in late-stage study
• Positive Sentiment: Major media confirm breakthrough and market reaction — CNBC and Barron's coverage highlight the trial's magnitude (large survival improvement), helping drive strong investor demand and a sharp intraday rally. Pancreatic Cancer Drug Daraxonrasib Succeeds in Trial (CNBC)
• Positive Sentiment: Market reaction and analyst attention — multiple market reports note the stock spiked to record levels as investors price in higher peak sales and potential partnerships or accelerated approval pathways for a high‑need indication. This Biotech Stock Soars 38% (Barron's)
• Neutral Sentiment: Market commentary notes upside but cautions — some analysts praise the PDAC data yet flag remaining questions (magnitude across subgroups, regulatory timing, commercial execution), leaving further upside uncertain until filings and label specifics. PDAC Data Wows Wall Street — Jury's Out On Further Upside (Seeking Alpha)
• Negative Sentiment: Planned equity and convertible debt offerings — the company filed to offer $750M of common stock and $250M of convertible senior notes (with customary overallotment options). That sizable capital raise can dilute existing shareholders and may cap some of the immediate upside from the trial news. Proposed Offerings of Common Stock and Convertible Senior Notes (GlobeNewswire)

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.